Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurological disease that causes the death of nerve cells that control voluntary muscles. Factors such as the increase in the incidence of ALS, a strong pipeline molecule, favorable reimbursement policies in some countries, and the expected launch of newer medications would drive the growth of the ALS treatment market globally.
The report titled “Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall ALS treatment market along with the market size and estimates for the duration of 2015–2025. The research study includes a thorough examination of market segments based on drug type (Riluzole, Edaravone, and Others) and geographical region.
Geographically, the global ALS treatment market is studied for the following regional markets:
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, opportunities, and pipeline analysis assists the readers in understanding the ongoing trends in the global ALS treatment market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the global ALS treatment market’s competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global ALS treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global ALS treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Based on drug type, the global amyotrophic lateral sclerosis (ALS) treatment market is segmented as follows:
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or Maladie de Charcot, is a neurological disease that causes nerve cells to gradually break down and die. According to the Centers for Disease Control and Prevention (CDC), 14,000 to 15,000 Americans had ALS in 2016. Factors such as increasing treatment awareness, strong pipeline molecules, a rising geriatric population, and the recent approval of new treatment medications are expected to drive the growth of the ALS treatment market globally. Currently, there is no cure for ALS; however, treatments are available to control symptoms and prevent unnecessary complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS, which include Riluzole (Rilutek) and Edaravone (Radicava).
Other medications are prescribed to control ALS symptoms, such as muscle cramps and spasms, spasticity, constipation, fatigue, excessive salivation, excessive phlegm, pain, depression, and sleep problems. It is studied that in the base year 2016, Riluzole (Rilutek) was a major revenue-generating segment due to high compliance because it is the only medication used in the treatment of ALS and works by reducing levels of a chemical messenger in the brain (glutamate) that is often present at higher levels in people with ALS.
The 2013 patent expiry of Rilutek has negatively impacted the growth of the ALS treatment market. On the other hand, the recently approved Radicava is expected to show the highest growth rate during the forecast period due to its applicability and higher cost, which are expected to drive market growth during the forecast period. Moreover, the expected launch of ALS treatment molecules such as AB-1010 (masitinib), Methycobal (mecobalamin), Arimoclomol, and CK-2017-357 (CK-357, tirasemtiv) would assist market growth during the forecast period.
For the purpose of this study, the global amyotrophic lateral sclerosis (ALS) treatment market is categorized into three segments:
- North America
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
It is observed that, in the base year 2016, North America dominated the ALS treatment market in terms of revenue due to factors such as an upsurge in funding by government agencies and private organizations in the healthcare system, an increase in the prevalence of neurological diseases, and higher treatment awareness that assisted market growth in North America. According to the National ALS Registry, in 2016, more than 12,000 people in the United States had a definite diagnosis of ALS, with a prevalence of 3.9 cases per 100,000 persons in the U.S. general population. According to the National Organization for Rare Disorders (NORD), ALS is a rare disorder; approximately 5,000 new cases are diagnosed each year in the United States.
Even though Riluzole is expensive, insurance policies such as Medicare and the National Organization for Rare Diseases also cover Riluzole. Furthermore, the Covis Patient Assistance Program helps U.S. citizens or residents who don’t have a health care plan or have been denied coverage for treatment, which is further driving the market’s growth in North America. It is estimated that Asia Pacific will show the highest growth rate during the forecast period due to increasing healthcare awareness, increasing partnerships of key players such as Biogen, Avicena, Mitsubishi Tanabe, and Sanofi with local manufacturers, populous countries, and developing economic conditions, which will fuel the ALS treatment market’s growth.